Breaking News

Charles River, INADcure Collaborate on Gene Therapy Manufacturing

CDMO will perform HQ plasmid production in support of Phase I/II clinical trials for Infantile Neuroaxonal Dystrophy.

Charles River Laboratories International, Inc. and INADcure Foundation, a nonprofit organization developing treatments for Infantile Neuroaxonal Dystrophy (INAD) and other forms of PLA2G6-related neurodegeneration (PLAN), entered into a plasmid DNA manufacturing alliance. The collaboration will leverage Charles River’s contract development and manufacturing organization services in High Quality (HQ) plasmid DNA production, to manufacture its leading candidate for Phase I/II clinical trials. I...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters